Teva to sell 79 drugs to gain approval for Allergan’s generic business
Teva Pharmaceutical Industries will sell the rights and assets related to 79 pharmaceutical products to settle the government’s anticompetitive claims surrounding its $40.5 billion purchase of Allergan’s generic drug business....
Subscription required to view this article.This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: